Update on Parkinson's disease

American Family Physician

Volumn 59, Issue 8, 1999, Pages 2155-2167

  Young, Rosabel ^a  

^a KING DREW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMINE OXIDASE (FLAVIN CONTAINING); BENZATROPINE MESILATE; BOTULINUM TOXIN; BROMOCRIPTINE MESILATE; CARBIDOPA PLUS LEVODOPA; DIPHENHYDRAMINE; HALOPERIDOL; METOCLOPRAMIDE; PERGOLIDE MESILATE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL;

ARTICLE; BLEPHAROSPASM; BRADYKINESIA; CEREBROVASCULAR DISEASE; DEGENERATIVE DISEASE; DIETARY INTAKE; DIFFERENTIAL DIAGNOSIS; DISEASE CONTROL; DYSTONIA; HUMAN; PARKINSON DISEASE; PHYSIOTHERAPY; RIGIDITY; SUBSTANTIA NIGRA; TREMOR;

ANTIPARKINSON AGENTS; HUMANS; INTERNET; NEUROSURGICAL PROCEDURES; PARKINSON DISEASE, SECONDARY; PATIENT EDUCATION; SELF-HELP GROUPS; TEACHING MATERIALS;

EID: 0033561334     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Mitchell SL, Kiely DK, Kiel DP, Lipsitz LA. The epidemiology, clinical characteristics, and natural history of older nursing home residents with a diagnosis of Parkinson's disease. J Am Geriatr Soc 1996;44:394-9.
2. Schoenberg BS. Descriptive epidemiology of Parkinson's disease: disease distribution and hypothesis formulation. Adv Neurol 1987;45:277-83.
3. Marder KS, Logroscino G, Alfaro B, Mejia H, Cote L, Mayeux R. Environmental risk factors for Parkinson's disease in a multi-ethnic urban community [Abstract]. Neurology 1997;48(3 suppl 2):A334.
4. Nelson LM, VanDenEeden SK, Tanner CM, Fross RD, Bernstein AL, Paroubeck LA, et al. Incidence of idiopathic Parkinson's disease in a health maintenance organization (HMO): variations by age, gender, and race/ethnicity [Abstract]. Neurology 1997;48(3 suppl 2):A334.
5. Schoenberg BS. Environmental risk factors for Parkinson's disease: the epidemiologic evidence. Can J Neurol Sci 1987; 14(3 suppl):407-13.
6. Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di lorio G, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1996;274:1197-9.
7. Mori H, Kondo T, Yokochi M, Matsumine H, Nakagawa-Hattori Y, Miyake T, et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1998;51:890-2.
8. Martinez-Martin P. Rating scales in Parkinson's disease. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. 2d ed. Baltimore: Williams & Wilkins, 1993:281-92.
9. Litvan I, Goetz CG, Jankovic J, Wenning GK, Booth V, Bartko JJ, et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol 1997;54:937-44.
10. Chabolla DR, Maraganore DM, Ahlskog JE, O'Brien PC, Rocca WA. Drug-induced parkinsonism as a risk factor for Parkinson's disease: a historical cohort study in Olmsted County, Minnesota. Mayo Clin Proc 1998;73:724-7.
11. Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings JL. Risk factors for depression in Parkinson disease. Arch Neurol 1997;54:625-30.
12. Camella CL, Nardine TM, Diederich NJ, Stebbins GT. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease [Abstract]. Neurology 1997;48(3 suppl 2):A359.
13. Cotzias GC, Papasitou PS, Geliene R. Modification of parkinsonism - chronic treatment with L-dopa. N Engl J Med 1969;280:337-45.
14. Markham CH, Diamond SG. Evidence to support early levodopa therapy in Parkinson disease. Neurology 1981;31:125-31.
15. Kuno S. Dilemma in the treatment of Parkinson's disease with L-dopa. Eur Neurol 1994:34:(suppl 3):17-9.
16. Lang AE, Lofano AM. Parkinson's disease. Second of two parts. N Engl J Med 1998;339:1130-43.
17. Adler CH, Stern M, Vernon G, Hurtig HI. Amantadine in advanced Parkinson's disease: good use of an old drug [Letter]. J Neurol 1997;244;336-7.
18. Lange KW, Kornhuber J, Steter P. Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev 1997;21:393-400.
19. Ogawa N, Kanazawa I, Kowa H, Kuno S, Mizuno Y, Tashiro K, et al. Nationwide multicenter prospective study on the long-term effect of bromocriptine for Parkinson's disease. Final report of a ten-year follow-up. Eur Neurol 1997;38(suppl 2):37-48.
20. Mizuno Y, Kondo T, Narabayashi H, Pergolide in the treatment of Parkinson's disease. Neurology 1995;45(3 suppl 3):S13-21.
21. Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, a monotherapy in mild to moderate. Parkinson's disease. Neurology 1997;49:724-8 [published erratum in Neurology 1997;49:838].
22. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997;49: 393-9 [published erratum in Neurology 1997; 49:1484].
23. Sethi KD, O'Brien CF, Hammerstad JP, Adler CH, Davis TL, Taylor RL, et al. Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Arch Neurol 1998;55:1211-6.
24. Ahlskog JE. Treatment of early Parkinson's disease: are complicated strategies justified? Mayo Clin Proc 1996;71:659-70.
25. Lieberman AN, Gopinathan G. Neophytides A, Foo SH. Deprenyl versus placebo in Parkinson disease: a double-blind study. N Y State J Med 1987;87:646-9.
26. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311:1602-7.
27. Heinonen EH, Myiiyla V. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Saf 1998;19:11-22.
28. Richard IH, Kurlan R. A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology 1997;49:1168-70.
29. Martinez-Martin R O'Brien CF. Extending levodopa action: COMT inhibition. Neurology 1998;50(6 suppl 6):S27-32.
30. Schelosky L, Benke T, Foewe WH. Effects of treatment with trihexyphenidyl on cognitive function in early Parkinson's disease. J Neural Transm Suppl 1991;33:125-32.
31. Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord 1995;10:333-6.
32. Markham CH, Brown WJ, Rand RW. Stereotaxic lesions in Parkinson's disease. Clinicopathological correlations. Arch Neurol 1966;15:480-97.
33. Benabid AL, Pollak P, Gao D, Hoffmann D, Limousin P, Gay E, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg 1996;84:203-14.
34. Fazzini E, Dogali M, Sterio D, Eidelberg D, Beric A. Stereotatic pallidotomy for Parkinson's disease: a long-term follow-up of unilateral pallidotomy. Neurology 1997;48:1273-7.
35. Limousin P, Krack P, Poliak P, Benazzouz A, Ardouin C, Hoffman D, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998;339:1105-11.
36. Obeso J, Rodriguez MC, Gorcspe AA, Guridi J, Alvarez L, Macias R. Surgical treatment of Parkinson's disease. Clin Neurol 1997;6:125-45.
37. Dunnett SB, Kendall AL, Watts C, Torres M. Neuronal cell transplantation for Parkinson's and Huntington's diseases. Br Med Bull 1997;53:757-76.
38. Goetz, CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-71.
39. Factor SA, Friedman JH. The emerging role of clozopine in the treatment of movement disorders. Mov Disord 1997;12:483-96.
40. Louis ED, Marder K, Cote L, Tang M, Mayeux R. Mortality from Parkinson disease. Arch Neurol 1997;54:260-4.